Five Prime Therapeutics Announces Updated Data in Mesothelioma…
Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting Objective response rate of 39% and disease control rate of 100% in patients at or below the maximum tol…